| REGENERON PHARMACEUTICALS, INC. (REGN) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | 2013-Dec-31 | |
| Fiscal Period | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | Q1-FY2014 | Q4-FY2013 | |
| Price to Sales | 5.34x | 4.10x | 3.92x | 4.84x | 5.42x | 8.23x | 8.45x | 7.93x | 7.17x | 6.71x | 6.12x | 7.14x | 6.35x | 5.39x | 4.49x | 4.51x | 4.16x | 4.69x | 4.72x | 5.42x | 5.96x | 7.38x | 9.34x | 7.53x | 6.18x | 4.52x | 5.15x | 6.71x | 5.91x | 6.74x | 5.89x | 6.01x | 6.76x | 8.53x | |||||||||||||||
| Price to Book | 2.46x | 1.89x | 1.86x | 2.32x | 2.62x | 3.89x | 4.04x | 3.85x | 3.62x | 3.53x | 3.23x | 3.76x | 3.41x | 3.45x | 3.09x | 3.74x | 3.56x | 3.68x | 3.87x | 4.16x | 4.60x | 5.78x | 7.62x | 4.35x | 3.66x | 2.85x | 3.45x | 4.67x | 4.53x | 5.45x | 5.09x | 5.55x | 6.46x | 7.77x | |||||||||||||||
| Price to Earnings | 16.62x | 12.77x | 12.49x | 15.14x | 17.44x | 24.49x | 26.38x | 26.93x | 23.79x | 22.02x | 18.05x | 21.11x | 17.81x | 13.76x | 11.23x | 9.39x | 8.27x | 9.08x | 9.43x | 12.45x | 14.42x | 18.55x | 23.12x | 23.17x | 19.16x | 13.97x | 16.28x | 18.17x | 16.22x | 23.86x | 22.97x | 25.52x | 33.11x | 36.80x | |||||||||||||||
| Price to Unlevered FCF | 15.01x | 11.53x | 11.74x | 17.23x | 17.41x | 26.84x | 28.01x | 21.92x | 20.47x | 16.82x | 16.38x | 20.62x | 15.41x | 13.04x | 7.55x | 8.75x | 9.43x | 10.70x | 25.75x | 19.26x | 19.35x | 26.92x | 23.10x | 23.67x | 16.68x | 12.63x | 14.86x | 17.83x | 18.07x | 21.10x | 18.32x | 23.20x | 30.36x | 41.60x | |||||||||||||||
| Debt to Asset Ratio | .23x | .22x | .22x | .22x | .22x | .22x | .21x | .21x | .23x | .22x | .22x | .22x | .23x | .24x | .24x | .26x | .27x | .30x | .33x | .36x | .37x | .37x | .23x | .25x | .25x | .26x | .27x | .25x | .27x | .28x | .30x | .30x | .30x | .32x | .38x | .36x | .34x | .34x | .36x | .35x | .36x | .26x | .29x | .34x | .32x | .31x | .32x | .34x | |
| Current Ratio | 4.06x | 4.60x | 4.93x | 4.73x | 5.28x | 5.44x | 5.27x | 5.69x | 5.18x | 5.45x | 5.45x | 5.06x | 5.36x | 5.12x | 4.76x | 3.56x | 3.71x | 3.57x | 3.12x | 3.63x | 3.89x | 2.12x | 4.21x | 3.67x | 4.03x | 3.88x | 4.58x | 4.47x | 4.04x | 3.62x | 3.59x | 3.82x | 3.63x | 3.75x | 2.80x | 2.56x | 3.64x | 3.37x | 3.41x | 3.59x | 3.64x | 3.80x | 4.31x | 3.18x | 5.36x | 5.46x | 6.13x | 6.01x | |